Skip to main content

Table 2 Elevated metabolic abnormalities and depression in breast cancer survivors

From: Increased depression and metabolic risk in postmenopausal breast cancer survivors

 

Control N = 28

BCS N = 28

Systolic blood pressure (mmHg)

121 ± 3

122 ± 2

Diastolic blood pressure (mmHg)

68 ± 1

68 ± 1

Hypertension medication usage (%)

43

56

Fasting glucose (mmol/L)

5.2 ± 0.1

5.7 ± 0.2b

Fasting insulin (pmol/L)

86 ± 7

97 ± 15

HOMA-IR

3.3 ± 0.3

4.1 ± 0.6

2-hr glucose (mmol/L)

7.1 ± 0.4

6.6 ± 0.6

Cholesterol (mmol/L)

4.8 ± 0.1

5.2 ± 0.2a

Triglycerides (mmol/L)

1.2 ± 0.1

1.4 ± 0.1

HDL-C (mmol/L)

1.4 ± 0.1

1.7 ± 0.1b

LDL-C (mmol/L)

2.8 ± 0.1

2.9 ± 0.2

Lipid lowering medication usage (%)

11

50c

Metabolic syndrome components (#)

1.7 ± 0.2

2.4 ± 0.3b

CES-D

6 ± 1

6 ± 1

Antidepressant medication usage (%)

14

43b

  1. Mean ± SEM
  2. HDL-C high-density lipoprotein cholesterol; LDL-C low-density lipoprotein cholesterol; CES-D Center for Epidemiologic Studies Depression Scale
  3. Different than control: P = 0.08; b P < 0.05; c P < 0.01